Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
about
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patientsUpdate on the treatment of patients with non-genotype 1 hepatitis C virus infectionPersonalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized StudyAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Hepatitis C in Argentina: epidemiology and treatment.Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settingsPeginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study.Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study.Response-guided and -unguided treatment of chronic hepatitis C.What's new in HCV genotype 2 treatment.Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.Hepatitis C therapy in non-genotype 1 patients: the near future.How to optimize HCV therapy in genotype 2 patients.Is genotype 3 of the hepatitis C virus the new villain?Treatment of hepatitis C virus genotype 3-infection.Optimal therapy of genotype-2 chronic hepatitis C: what's new?Therapy for hepatitis C genotype 3: moving forward.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.[Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfected with HIV].Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study.Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin.New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2.Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy.Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads.KASL clinical practice guidelines: management of hepatitis C.Hepatitis C virus infection: looking for interferon free regimens.
P2860
Q24200534-9382BD00-466D-45CA-857A-63F30D72E3B7Q27000806-3EE7BA15-8E37-4C93-B9CA-5A8364F908C5Q28608449-A4C86A64-E069-4EBF-B6CE-6DEE66280E8AQ30250088-410A07B4-E085-4351-A656-91AACD9659C1Q30417045-C5B9B49B-0BCD-43B7-92A0-9F8A5ADCACE9Q33559298-843DCA20-4D75-47A7-AC03-8141ABB4EA83Q33706886-BD7E5551-B709-4FD9-9367-01BBD3B00051Q35069531-DBCA482D-9FA8-4B1A-9CD3-F0949789722EQ35803105-0820D344-F07C-44E4-AB86-24D5BB9D6899Q36163864-9444BF95-F2F2-4A69-A266-B470205DA65AQ36296058-97DED913-AFF3-4683-9E1A-133B2CD5261FQ36572537-387E8B38-FE82-4F67-9C59-8A4F94533AD5Q37636210-EC3D92AD-C4EB-4779-8072-8E9EA1025085Q37972765-1EF159A3-9BF8-445F-BCEF-C6EEBAECCB36Q37972773-AB3C8F13-E998-4D8C-8906-9B3AB01C0F64Q37972774-68AC727D-75DD-4D2C-8D50-2CD8AF8AB006Q38023869-08F1D304-35D9-45CE-B130-478EFB3CE51FQ38071386-BDE62192-590B-41F3-ABF7-0EF45ADA76A7Q38155123-37B7190B-7800-4222-A8DA-A68A36029B1FQ38174244-3135937D-F597-43A1-AA5B-07F321345BDCQ38295810-7B6F5F3D-A0D7-417A-82E0-8E8762DC3A8DQ38476041-61ABCD13-BD93-46F0-99B2-1A82D2EE2EC2Q39104215-A212B025-2C7C-48EA-88E1-9B2570834C2DQ41412067-D2B8D22A-018E-420F-9279-01F662710A02Q41658810-A1CAE99F-FB60-4F79-B967-A8DE82C16E52Q42181724-0AF0D1D6-78E1-439E-B010-D54D9F425A81Q42225912-E7A1A004-B4DE-4952-AA4B-323AD9A3598BQ42259157-45735856-C929-4578-A40F-DFC8DF924557Q42274008-79245F7A-F76D-4019-9C58-83C47A33CB35Q42980225-674770C4-6741-4253-A019-F6C71384AF1EQ42986651-7FA10996-3FB8-4735-91B4-4CBD117BC7CCQ42993287-BFCF02E7-F8A2-4886-A7A9-65B7142DE2E4Q45359763-0FD78460-B12D-4BA3-A7C6-9ADCD67D9B8EQ45722996-FDFB49CC-B4FB-4758-8971-2902D69222DFQ50101206-7FCA2913-E73E-44EA-BF02-B1A3E8189CB5Q50552266-461993EA-4AC6-4AD8-9B4E-84763F1D3F79Q50552503-5028D3E5-BD03-4DC3-9687-1080BB376B54Q51836024-44E1C373-0B61-4BE8-934E-5BA1471A0294Q51873522-E08E66DF-BF4D-4744-8CE0-134E106762A8
P2860
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Response-guided peg-interferon ...... d implications for the future.
@en
Response-guided peg-interferon ...... d implications for the future.
@nl
type
label
Response-guided peg-interferon ...... d implications for the future.
@en
Response-guided peg-interferon ...... d implications for the future.
@nl
prefLabel
Response-guided peg-interferon ...... d implications for the future.
@en
Response-guided peg-interferon ...... d implications for the future.
@nl
P2093
P2860
P356
P1433
P1476
Response-guided peg-interferon ...... d implications for the future.
@en
P2093
Alessandra Mangia
Carine Richou
Donald M Jensen
Frances Sheppard
Jean-Paul Cervoni
Jose M Sanchez-Tapias
Maria Buti
Peter Ferenci
Thierry Thévenot
Vincent Di Martino
P2860
P304
P356
10.1002/HEP.24480
P407
P577
2011-07-19T00:00:00Z